Clinical Trials of Texas

Recent papers from Clinical Trials of Texas

1. Splenic neuromodulation as monotherapy and in combination with biologic or targeted synthetic DMARDs for difficult-to-treat rheumatoid arthritis (ConsiderRAte): a randomised, sham-controlled, early feasibility trialEClinicalMedicine · 2026
2. Evaluating Underrepresentation in Cancer Clinical Trial Enrollment Across Three National Cancer Institute–Designated Cancer Centers: A Retrospective Demographic StudyJCO oncology advances. · 2026
3. Pregabalin naproxencarbil in acute post-bunionectomy pain: a randomized clinical trialPAIN Reports · 2026
4. Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trialNature Medicine · 2025
5. A Multi‐Centre, Randomised, Controlled Clinical Trial Assessing Cryopreserved Ultra‐Thick Human Amniotic Membrane in the Treatment of Complex Diabetic Foot UlcersWound Repair and Regeneration · 2025
6. Human Placenta‐Derived Cells (PDA‐002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi‐Center, Randomised, Double‐Blind, Placebo‐Controlled TrialInternational Wound Journal · 2025
7. Viloxazine Extended-Release Capsules in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: Results of a Long-Term, Phase 3, Open-Label Extension TrialCNS Drugs · 2025
8. How does internal fixation compared with arthroplasty affect quality of life for patients who have suffered femoral neck fractures?OTA International The Open Access Journal of Orthopaedic Trauma · 2025
9. Accuracy of the 15.5-Day G7 iCGM in Adults with DiabetesDiabetes Technology & Therapeutics · 2025
10. Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescentsHuman Vaccines & Immunotherapeutics · 2025
11. Safety and Immunogenicity of SARS-CoV-2 Spike Receptor-Binding Domain and N-Terminal Domain mRNA VaccineThe Journal of Infectious Diseases · 2025
12. Phase 1 Trials of PNPLA3 siRNA in I148M Homozygous Patients with MAFLDNew England Journal of Medicine · 2024
13. Abstract PO1-26-03: Activity of alpelisib in a panel of breast XPDX models harboring hotspot and uncommon PIK3CA mutationsCancer Research · 2024
14. Abstract CT077: An open-label phase 1 study to investigate SGN-CEACAM5C in adults with advanced solid tumors (SGNCEA5C-001, Trial in Progress)Cancer Research · 2024
15. Abstract CT191: First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim dataCancer Research · 2024
16. Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label studyDiabetes Obesity and Metabolism · 2024
17. Abstract 6899: Enfortumab vedotin (EV): Efficacy comparison with trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) and its potential for combination benefit in bladder cancer XPDX modelsCancer Research · 2024
18. Abstract 6891: Establishment and characterization of a panel of naïve and pretreated small cell lung cancer (SCLC) XPDX modelsCancer Research · 2024
19. Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatmentMolecular Cancer Therapeutics · 2023
20. First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid TumorsClinical Cancer Research · 2023